<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01582477</url>
  </required_header>
  <id_info>
    <org_study_id>MA402S23B701</org_study_id>
    <nct_id>NCT01582477</nct_id>
  </id_info>
  <brief_title>TAP-patients With Robotic Assisted Lap Prostatectomy</brief_title>
  <acronym>TAP</acronym>
  <official_title>Evaluation of the Safety and Efficacy of EXPAREL When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) for Prolonged Postsurgical Analgesia in Subjects Undergoing Robot-assisted Laparoscopic Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and efficacy of EXPAREL when administered
      via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical
      analgesia in men undergoing robot-assisted laparoscopic prostatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the safety and efficacy of EXPAREL when administered via infiltration into the
      transversus abdominis plane (TAP) to provide prolonged postsurgical analgesia in men
      undergoing robot-assisted laparoscopic prostatectomy. The primary endpoint is the duration of
      abdominal analgesia from the infiltration into the TAP as measured by the time to the
      subject's first postsurgical opioid administration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Duration of Abdominal Analgesia From Infiltration Into the TAP</measure>
    <time_frame>First postsurgical administration of an opioid</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject Reported Postsurgical Pain</measure>
    <time_frame>1, 2, 6, 12, 24, 48, 72, 96 hours and 10 days after TAP</time_frame>
    <description>11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician/Healthcare Professional Assessed Postsurgical Pain</measure>
    <time_frame>1, 2, 6, 12, 24 hours after TAP</time_frame>
    <description>11-point NRS (0-10, 0=no pain, 10=worst possible pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.</measure>
    <time_frame>48, 72, 96 hours, and 10 days</time_frame>
    <description>Number of pills</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Prespecified Opioid-related Adverse Events</measure>
    <time_frame>Until hospital discharge order was written, anticipated at 24 hours.</time_frame>
    <description>Number of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Rating of Subject Satisfaction With Postsurgical Pain Control</measure>
    <time_frame>24 hours, 72 hours, and day 10</time_frame>
    <description>Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Postsurgical Pain</condition>
  <condition>Analgesia</condition>
  <condition>Prostatectomy</condition>
  <arm_group>
    <arm_group_label>EXPAREL 20 mL (undiluted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mL (266 mg) undiluted EXPAREL with 133 mg infiltrated on each the right and left side of the abdomen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPAREL 40 mL (diluted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mL (266 mg) EXPAREL diluted with an equal volume of preservative-free 0.9% normal saline to a total of 40 mL and infiltrated equally to the right and left side of the abdomen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL 20 mL</intervention_name>
    <description>EXPAREL 266 mg (undiluted)</description>
    <arm_group_label>EXPAREL 20 mL (undiluted)</arm_group_label>
    <other_name>bupivacaine liposome injectable suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXPAREL 40 mL</intervention_name>
    <description>EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.</description>
    <arm_group_label>EXPAREL 40 mL (diluted)</arm_group_label>
    <other_name>bupivacaine liposome injectable suspension</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male subjects, aged 18-75.

          -  American Society of Anesthesiology (ASA) physical status 1-3.

          -  Undergoing robot-assisted laparoscopic prostatectomy performed by a single surgeon
             (Ingolf Tuerk, MD).

          -  Subjects must be physically and mentally able to participate in the study and complete
             all study assessments.

          -  Subjects must be able to give fully informed consent to participate in this study
             after demonstrating a good understanding of the risks and benefits of the TAP
             infiltration.

        Exclusion Criteria:

          -  Demonstrated hypersensitivity or idiosyncratic reactions to amide-type local
             anesthetics.

          -  Inability to tolerate oxycodone with acetaminophen (e.g. Percocet).

          -  Any subject whose anatomy or surgical procedure in the opinion of the Investigator
             might preclude the potential successful performance of a TAP.

          -  Any subject who in the opinion of the Investigator might be harmed or be a poor
             candidate for participation in the study.

          -  Subjects who have received any investigational drug within 30 days prior to study drug
             administration or planned administration of another investigational product or
             procedure during their participation in this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Sternlicht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steward St. Elizabeth's</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steward St. Elizabeth's</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <results_first_submitted>February 26, 2013</results_first_submitted>
  <results_first_submitted_qc>May 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2013</results_first_posted>
  <last_update_submitted>May 5, 2013</last_update_submitted>
  <last_update_submitted_qc>May 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAP, robot-assisted prostatectomy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EXPAREL 20 mL</title>
          <description>Group receiving EXPAREL 20 mL</description>
        </group>
        <group group_id="P2">
          <title>EXPAREL 40 mL</title>
          <description>Group receiving EXPAREL 40 mL</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EXPAREL 20 mL</title>
          <description>Group receiving EXPAREL 20 mL</description>
        </group>
        <group group_id="B2">
          <title>EXPAREL 40 mL</title>
          <description>Group receiving EXPAREL 40 mL</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="7.24"/>
                    <measurement group_id="B2" value="61.7" spread="7.01"/>
                    <measurement group_id="B3" value="61.2" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Duration of Abdominal Analgesia From Infiltration Into the TAP</title>
        <time_frame>First postsurgical administration of an opioid</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure>
          <title>The Duration of Abdominal Analgesia From Infiltration Into the TAP</title>
          <population>Per protocol</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="0.27" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.44" lower_limit="0.40" upper_limit="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Reported Postsurgical Pain</title>
        <description>11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)</description>
        <time_frame>1, 2, 6, 12, 24, 48, 72, 96 hours and 10 days after TAP</time_frame>
        <population>Data shown are from the 72-hour time point</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Reported Postsurgical Pain</title>
          <description>11-point numeric rating scale (NRS) (0-10, where 0=no pain, 10=worst possible pain)</description>
          <population>Data shown are from the 72-hour time point</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.64"/>
                    <measurement group_id="O2" value="1.9" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician/Healthcare Professional Assessed Postsurgical Pain</title>
        <description>11-point NRS (0-10, 0=no pain, 10=worst possible pain)</description>
        <time_frame>1, 2, 6, 12, 24 hours after TAP</time_frame>
        <population>24 hour NRS is reported</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure>
          <title>Physician/Healthcare Professional Assessed Postsurgical Pain</title>
          <description>11-point NRS (0-10, 0=no pain, 10=worst possible pain)</description>
          <population>24 hour NRS is reported</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="1.75"/>
                    <measurement group_id="O2" value="2.5" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.</title>
        <description>Number of pills</description>
        <time_frame>48, 72, 96 hours, and 10 days</time_frame>
        <population>96 hour measurement given</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure>
          <title>Total Postsurgical Oxycodone/Acetaminophen Consumption From Hospital Discharge Through Hour 96.</title>
          <description>Number of pills</description>
          <population>96 hour measurement given</population>
          <units>Number of tablets</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="4.25"/>
                    <measurement group_id="O2" value="4.8" spread="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Prespecified Opioid-related Adverse Events</title>
        <description>Number of subjects</description>
        <time_frame>Until hospital discharge order was written, anticipated at 24 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Prespecified Opioid-related Adverse Events</title>
          <description>Number of subjects</description>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Rating of Subject Satisfaction With Postsurgical Pain Control</title>
        <description>Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)</description>
        <time_frame>24 hours, 72 hours, and day 10</time_frame>
        <population>72 hour reported subject satisfaction at</population>
        <group_list>
          <group group_id="O1">
            <title>EXPAREL 20 mL</title>
            <description>Group receiving EXPAREL 20 mL</description>
          </group>
          <group group_id="O2">
            <title>EXPAREL 40 mL</title>
            <description>Group receiving EXPAREL 40 mL</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Rating of Subject Satisfaction With Postsurgical Pain Control</title>
          <description>Mean of subject satisfaction offered on a 5-point Likert scale (1 = extremely dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, 5 = extremely satisfied)</description>
          <population>72 hour reported subject satisfaction at</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.64" spread="0.255"/>
                    <measurement group_id="O2" value="4.64" spread="0.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EXPAREL 20 mL</title>
          <description>Group receiving EXPAREL 20 mL</description>
        </group>
        <group group_id="E2">
          <title>EXPAREL 40 mL</title>
          <description>Group receiving EXPAREL 40 mL</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Post-procedural Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Sternlicht, MD</name_or_title>
      <organization>St. Elizabeth's Medical Center</organization>
      <phone>617-789-2777</phone>
      <email>andrew.sternlicht@steward.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

